Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.78
+6.2%
$3.91
$2.90
$11.16
$333.61M0.182.88 million shs2.65 million shs
Amgen Inc. stock logo
AMGN
Amgen
$283.64
+1.3%
$293.85
$253.30
$339.17
$152.70B0.491.79 million shs2.30 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.35
-2.2%
$743.84
$623.78
$942.35
$688.27B0.475.28 million shs3.95 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$432.89
+0.4%
$350.02
$200.63
$443.00
$9.61B-1.02394,410 shs281,201 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$55.15
-1.8%
$59.46
$45.05
$138.22
$246.60B0.6614.63 million shs15.49 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$102.12
-2.3%
$90.03
$45.90
$106.52
$6.78B2.23544,176 shs533,575 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.98
+1.7%
$31.22
$18.92
$81.73
$3.03B0.739.57 million shs5.24 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+6.18%-1.31%+4.56%-32.74%-41.85%
Amgen Inc. stock logo
AMGN
Amgen
+1.26%-1.41%-0.36%-2.30%-14.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.14%-0.83%-2.66%-5.67%-23.24%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.39%-1.13%+28.03%+55.59%+76.44%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.78%-2.40%+21.71%-26.18%-59.00%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-2.34%-1.00%+13.45%+49.93%+117.79%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.70%-0.26%-15.37%-3.05%-53.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.78
+6.2%
$3.91
$2.90
$11.16
$333.61M0.182.88 million shs2.65 million shs
Amgen Inc. stock logo
AMGN
Amgen
$283.64
+1.3%
$293.85
$253.30
$339.17
$152.70B0.491.79 million shs2.30 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.35
-2.2%
$743.84
$623.78
$942.35
$688.27B0.475.28 million shs3.95 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$432.89
+0.4%
$350.02
$200.63
$443.00
$9.61B-1.02394,410 shs281,201 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$55.15
-1.8%
$59.46
$45.05
$138.22
$246.60B0.6614.63 million shs15.49 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$102.12
-2.3%
$90.03
$45.90
$106.52
$6.78B2.23544,176 shs533,575 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.98
+1.7%
$31.22
$18.92
$81.73
$3.03B0.739.57 million shs5.24 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+6.18%-1.31%+4.56%-32.74%-41.85%
Amgen Inc. stock logo
AMGN
Amgen
+1.26%-1.41%-0.36%-2.30%-14.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.14%-0.83%-2.66%-5.67%-23.24%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.39%-1.13%+28.03%+55.59%+76.44%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.78%-2.40%+21.71%-26.18%-59.00%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-2.34%-1.00%+13.45%+49.93%+117.79%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.70%-0.26%-15.37%-3.05%-53.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.57
Moderate Buy$17.40360.32% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.32
Hold$304.437.33% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.70
Moderate Buy$950.1730.81% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.90
Moderate Buy$471.138.83% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$81.0046.88% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.07
Buy$101.57-0.54% Downside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$86.92222.18% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$500.00
9/3/2025
Amgen Inc. stock logo
AMGN
Amgen
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduceHold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate SellHold
8/26/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/26/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$390.00 ➝ $554.00
8/25/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$328.00 ➝ $342.00
8/22/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/20/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$483.00 ➝ $485.00
8/20/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHoldStrong Sell
8/19/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$105.00 ➝ $70.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K16,681.14N/AN/A$1.74 per share2.17
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.57$30.37 per share9.34$10.93 per share25.95
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.26$14.22 per share51.09$15.03 per share48.33
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$180.13M53.35N/AN/A$34.59 per share12.51
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B5.85$3.89 per share14.16$4.66 per share11.83
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M52.12N/AN/A$0.35 per share291.77
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2323.1913.262.4618.96%174.71%13.12%10/29/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.4723.341.0125.91%92.72%16.89%10/29/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6415.1511.831.9235.60%78.64%24.51%11/5/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
8/5/2025Q2 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 million
8/5/2025Q2 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44-$0.58-$0.14-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Amgen Inc. stock logo
AMGN
Amgen
$9.523.36%N/A77.84%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.83%N/A39.22%11 Years
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.49%N/A22.53%N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest NVO, LLY, AMGN, ALT, VKTX, MDGL, and RYTM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
8/6/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.09
20.44
20.44
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.17
5.11
4.78
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.52
0.78
0.56
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.79
2.64
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
25.86
25.86
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5088.26 million84.37 millionOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.27 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.23 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million17.43 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14066.42 million62.37 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.44 million107.84 millionOptionable

Recent News About These Companies

Braidwell LP Trims Position in Viking Therapeutics, Inc. $VKTX
Brokers Issue Forecasts for VKTX Q3 Earnings
Q3 Earnings Forecast for VKTX Issued By B. Riley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.78 +0.22 (+6.18%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$3.75 -0.03 (-0.79%)
As of 09/5/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Amgen stock logo

Amgen NASDAQ:AMGN

$283.64 +3.54 (+1.26%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$280.96 -2.69 (-0.95%)
As of 09/5/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$726.35 -16.56 (-2.23%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$725.84 -0.52 (-0.07%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$432.89 +1.68 (+0.39%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$433.09 +0.20 (+0.05%)
As of 09/5/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$55.15 -0.99 (-1.77%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$55.20 +0.05 (+0.10%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$102.12 -2.45 (-2.34%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$100.11 -2.01 (-1.97%)
As of 09/5/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.98 +0.45 (+1.70%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$26.82 -0.16 (-0.58%)
As of 09/5/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.